Aswin K. Mohan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aswin K. Mohan has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Joyisa Deb
Department of Transfusion Medicine All India Institute of Medical Sciences Guwahati India
4 shared publications - Manideepa Maji
Hull York Medical School, University of Hull, Hull HU6 7RX, UK
4 shared publications - Saikat Mandal
Translational Medical Sciences, School of Medicine, University of Nottingham
4 shared publications - Arkadeep Dhali
Department of Gastroenterology, Queen’s University Belfast, Belfast BT7 1NN, UK
3 shared publications - Arun Rajendran
Additional Professor & Head of Department, Department of Transfusion Medicine & Blood Bank, All India Institute of Medical Sciences, Bibinagar, India
3 shared publications - Davood Ub
Assistant Professor, Department of Transfusion Medicine & Blood Bank, All India Institute of Medical Sciences, Bibinagar, India
3 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by BMJ in Open Heart
- Vol. 13 (2) , e004486
Infection risk and clinical outcomes with intravenous iron in adults with heart failure and iron deficiency: a systematic review and meta-analysis of randomised controlled trials
- 9 November 2026
- Published by BMJ in Open Heart
- Vol. 13 (2) , e004486
Open AccessInfection risk and clinical outcomes with intravenous iron in adults with heart failure and iron deficiency: a systematic review and meta-analysis of randomised controlled trials
- Open Access
Does Parenteral Iron Increase the Risk of Infection in Patients with Gastrointestinal Cancer? A Systematic Review and Meta-Analysis
Background: Parenteral iron is increasingly used to treat iron deficiency anaemia in patients with gastrointestinal cancer, particularly in the perioperative setting. However, concerns persist that intravenous iron could increase the risk of infection. We conducted a systematic review and meta-analysis to evaluate infectious complications and other relevant clinical outcomes after parenteral iron in gastrointestinal cancer. Methods: Embase, MEDLINE, CENTRAL and Scopus were searched from database inception to 20 February 2026, with additional records identified through citation searching. Comparative studies were eligible if they included adults with gastrointestinal cancer and compared parenteral iron with oral iron, placebo, no iron or standard care. Randomised and non-randomised comparative studies were included. The primary outcome was infection or infective complications. Secondary outcomes included length of hospital stay, hospital readmission and short-term mortality. Risk ratios (RRs) and mean differences (MDs) were pooled using random-effects models. Results: The search identified 2771 records. After removing 458 duplicates, 2313 records were screened, and 210 full texts were assessed. Fourteen comparative studies were included: four randomised controlled trials and ten non-randomised studies. Nine studies contributed to the primary infection analysis, including 899 patients receiving parenteral iron and 768 controls. Infection occurred in 126 patients in the parenteral iron group and 104 controls. Parenteral iron was not associated with an increased risk of infection (RR 1.07, 95% CI 0.71–1.62; p = 0.754; I2 = 57%). Restriction to randomised trials also showed no significant increase in infection risk (RR 1.17, 95% CI 0.56–2.43). Thirteen studies reported length of stay, with no meaningful difference between groups (MD: −0.05 days, 95% CI: −0.66 to 0.57). Four studies reported hospital readmission, with no significant difference between parenteral iron and control (RR 0.76, 95% CI 0.35–1.64; p = 0.480; I2 = 0%). Mortality analyses were event-limited, with no significant difference in 30-day mortality (RR 0.49, 95% CI 0.09–2.61) or 90-day mortality (RR 0.69, 95% CI 0.35–1.36). Conclusions: In patients with gastrointestinal cancer, parenteral iron was not associated with increased infection risk, prolonged hospital stay, higher readmission or increased short-term mortality. These findings provide reassuring evidence regarding the perioperative safety of parenteral iron, although confidence in the estimate is limited by observational evidence and heterogeneous definitions of infection.
Open AccessDoes Parenteral Iron Increase the Risk of Infection in Patients with Gastrointestinal Cancer? A Systematic Review and Meta-Analysis
Background: Parenteral iron is increasingly used to treat iron deficiency anaemia in patients with gastrointestinal cancer, particularly in the perioperative setting. However, concerns persist that intravenous iron could increase the risk of infection. We conducted a systematic review and meta-analysis to evaluate infectious complications and other relevant clinical outcomes after parenteral iron in gastrointestinal cancer. Methods: Embase, MEDLINE, CENTRAL and Scopus were searched from database inception to 20 February 2026, with additional records identified through citation searching. Comparative studies were eligible if they included adults with gastrointestinal cancer and compared parenteral iron with oral iron, placebo, no iron or standard care. Randomised and non-randomised comparative studies were included. The primary outcome was infection or infective complications. Secondary outcomes included length of hospital stay, hospital readmission and short-term mortality. Risk ratios (RRs) and mean differences (MDs) were pooled using random-effects models. Results: The search identified 2771 records. After removing 458 duplicates, 2313 records were screened, and 210 full texts were assessed. Fourteen comparative studies were included: four randomised controlled trials and ten non-randomised studies. Nine studies contributed to the primary infection analysis, including 899 patients receiving parenteral iron and 768 controls. Infection occurred in 126 patients in the parenteral iron group and 104 controls. Parenteral iron was not associated with an increased risk of infection (RR 1.07, 95% CI 0.71–1.62; p = 0.754; I2 = 57%). Restriction to randomised trials also showed no significant increase in infection risk (RR 1.17, 95% CI 0.56–2.43). Thirteen studies reported length of stay, with no meaningful difference between groups (MD: −0.05 days, 95% CI: −0.66 to 0.57). Four studies reported hospital readmission, with no significant difference between parenteral iron and control (RR 0.76, 95% CI 0.35–1.64; p = 0.480; I2 = 0%). Mortality analyses were event-limited, with no significant difference in 30-day mortality (RR 0.49, 95% CI 0.09–2.61) or 90-day mortality (RR 0.69, 95% CI 0.35–1.36). Conclusions: In patients with gastrointestinal cancer, parenteral iron was not associated with increased infection risk, prolonged hospital stay, higher readmission or increased short-term mortality. These findings provide reassuring evidence regarding the perioperative safety of parenteral iron, although confidence in the estimate is limited by observational evidence and heterogeneous definitions of infection.
- Open Access
- 26 January 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (2) , 61
Comparison of safety and efficacy of liberal versus restrictive red blood cell transfusion thresholds on the quality of life in patients with myelodysplastic syndromes: a systematic review and meta-analysis
Myelodysplastic syndromes (MDS) are clonal stem cell disorders managed by risk stratification: lower-risk disease receives erythropoiesis-stimulating agents; higher-risk disease receives azacitidine. Red blood cell (RBC) transfusions manage symptomatic anaemia and improve quality of life (QoL) but carry risks of iron overload and alloimmunisation. No standardised transfusion strategy exists, requiring systematic evidence synthesis comparing liberal versus restrictive haemoglobin (Hb) thresholds for their effects on quality of life and transfusion-related complications. We performed a systematic review evaluating liberal versus restrictive RBC transfusion thresholds in adults with MDS not undergoing curative treatment such as stem cell transplantation. Primary outcome was health-related QoL measured by validated instruments. Secondary outcomes included mortality, transfusion reaction, iron overload, RBC utilisation and rise in ferritin level. Of 4,295 records screened, 212 articles underwent full-text review, with three RCTs meeting inclusion criteria. Liberal transfusion strategies were associated with improved QoL compared to restrictive approaches, with pooled standardised mean difference (Hedges g) of 0.54 (95% CI 0.06–1.02; p = 0.33; I²=9.7%). Subgroup analysis of EQ‑5D outcomes across studies revealed minimal but statistically significant difference between strategies (pooled mean difference 0.084; 95% CI: 0.033 to 0.134). Mortality (hazard ratio 0.913; 95% CI 0.167–4.98) and transfusion reactions (risk difference − 0.01; 95% CI-0.10 to 0.09) did not differ. Notably, liberal thresholds required average of 4 additional RBC units per patient (95% CI 1.43–6.79), raising concerns about iron overload (rise in ferritin; mean difference 868 µg/L; 95% CI 482–1255). Limited evidence suggests that liberal transfusion strategies in MDS may improve short-term QoL but at the cost of increased transfusion burden, with no clear impact on survival or safety. A patient-centred, multidisciplinary approach remains essential when tailoring transfusion thresholds. The study protocol has been registered in PROSPERO (CRD420251085221). https://www.crd.york.ac.uk/PROSPERO/view/CRD420251085221 .
- 26 January 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (2) , 61
Open AccessComparison of safety and efficacy of liberal versus restrictive red blood cell transfusion thresholds on the quality of life in patients with myelodysplastic syndromes: a systematic review and meta-analysis
Myelodysplastic syndromes (MDS) are clonal stem cell disorders managed by risk stratification: lower-risk disease receives erythropoiesis-stimulating agents; higher-risk disease receives azacitidine. Red blood cell (RBC) transfusions manage symptomatic anaemia and improve quality of life (QoL) but carry risks of iron overload and alloimmunisation. No standardised transfusion strategy exists, requiring systematic evidence synthesis comparing liberal versus restrictive haemoglobin (Hb) thresholds for their effects on quality of life and transfusion-related complications. We performed a systematic review evaluating liberal versus restrictive RBC transfusion thresholds in adults with MDS not undergoing curative treatment such as stem cell transplantation. Primary outcome was health-related QoL measured by validated instruments. Secondary outcomes included mortality, transfusion reaction, iron overload, RBC utilisation and rise in ferritin level. Of 4,295 records screened, 212 articles underwent full-text review, with three RCTs meeting inclusion criteria. Liberal transfusion strategies were associated with improved QoL compared to restrictive approaches, with pooled standardised mean difference (Hedges g) of 0.54 (95% CI 0.06–1.02; p = 0.33; I²=9.7%). Subgroup analysis of EQ‑5D outcomes across studies revealed minimal but statistically significant difference between strategies (pooled mean difference 0.084; 95% CI: 0.033 to 0.134). Mortality (hazard ratio 0.913; 95% CI 0.167–4.98) and transfusion reactions (risk difference − 0.01; 95% CI-0.10 to 0.09) did not differ. Notably, liberal thresholds required average of 4 additional RBC units per patient (95% CI 1.43–6.79), raising concerns about iron overload (rise in ferritin; mean difference 868 µg/L; 95% CI 482–1255). Limited evidence suggests that liberal transfusion strategies in MDS may improve short-term QoL but at the cost of increased transfusion burden, with no clear impact on survival or safety. A patient-centred, multidisciplinary approach remains essential when tailoring transfusion thresholds. The study protocol has been registered in PROSPERO (CRD420251085221). https://www.crd.york.ac.uk/PROSPERO/view/CRD420251085221 .
- 12 January 2026
- Published by Elsevier in Transfusion Clinique et Biologique
“Catch Them Young”: An Elementary Idea to Sculpt a Generation of Superheroes
- 12 January 2026
- Published by Elsevier in Transfusion Clinique et Biologique
“Catch Them Young”: An Elementary Idea to Sculpt a Generation of Superheroes
- 7 November 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1-3
Post-Transfusion Hyperbilirubinemia: A Case-Based Root Cause Analysis and Quality Systems Perspective from a Blood Storage Centre
- 7 November 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (5) , 1-3
Post-Transfusion Hyperbilirubinemia: A Case-Based Root Cause Analysis and Quality Systems Perspective from a Blood Storage Centre
- Open Access
- 10 October 2025
- Published by Springer Nature in Research Square
Comparison of safety and efficacy of liberal versus restrictive red blood cell transfusion thresholds on the quality of life in patients with myelodysplastic syndromes: a systematic review and meta-analysis
Background: Myelodysplastic syndromes (MDS) are primarily managed with red blood cell (RBC) transfusions, as stem cell transplantation is unsuitable for most patients. Anaemia, presenting with fatigue, pallor, and dyspnoea, markedly impairs quality of life (QoL), making selection of optimal haemoglobin (Hb) thresholds for transfusion a key clinical challenge. However, comparative evidence for liberal versus restrictive transfusion strategies remains limited. Methods: We performed a systematic review evaluating liberal versus restrictive RBC transfusion thresholds in adults with MDS not undergoing curative treatment such as stem cell transplantation. Primary outcome was health-related QoL measured by validated instruments. Secondary outcomes included mortality, transfusion reaction, iron overload, RBC utilisation and rise in ferritin level. Results: Of 4,295 records screened, 212 articles underwent full-text review, with three RCTs meeting inclusion criteria. Liberal transfusion strategies were associated with improved QoL compared to restrictive approaches, with pooled standardised mean difference (Hedges g) of 0.54 (95% CI 0.06–1.02; p = 0.33; I²=9.7%). Subgroup analysis of EQ‑5D outcomes across studies revealed minimal but statistically significant difference between strategies (pooled mean difference 0.084; 95% CI: 0.033 to 0.134). Mortality (hazard ratio 0.913; 95% CI 0.167–4.98) and transfusion reactions (risk difference − 0.01; 95% CI-0.10 to 0.09) did not differ. Notably, liberal thresholds required average of 4 additional RBC units per patient (95% CI 1.43–6.79), raising concerns about iron overload (rise in ferritin; mean difference 868 µg/L; 95% CI 482–1255). Conclusion: Limited evidence suggests that liberal transfusion strategies in MDS may improve short-term QoL but at the cost of increased transfusion burden, with no clear impact on survival or safety. A patient-centred, multidisciplinary approach remains essential when tailoring transfusion thresholds.
- 10 October 2025
- Published by Springer Nature in Research Square
Open AccessComparison of safety and efficacy of liberal versus restrictive red blood cell transfusion thresholds on the quality of life in patients with myelodysplastic syndromes: a systematic review and meta-analysis
Background: Myelodysplastic syndromes (MDS) are primarily managed with red blood cell (RBC) transfusions, as stem cell transplantation is unsuitable for most patients. Anaemia, presenting with fatigue, pallor, and dyspnoea, markedly impairs quality of life (QoL), making selection of optimal haemoglobin (Hb) thresholds for transfusion a key clinical challenge. However, comparative evidence for liberal versus restrictive transfusion strategies remains limited. Methods: We performed a systematic review evaluating liberal versus restrictive RBC transfusion thresholds in adults with MDS not undergoing curative treatment such as stem cell transplantation. Primary outcome was health-related QoL measured by validated instruments. Secondary outcomes included mortality, transfusion reaction, iron overload, RBC utilisation and rise in ferritin level. Results: Of 4,295 records screened, 212 articles underwent full-text review, with three RCTs meeting inclusion criteria. Liberal transfusion strategies were associated with improved QoL compared to restrictive approaches, with pooled standardised mean difference (Hedges g) of 0.54 (95% CI 0.06–1.02; p = 0.33; I²=9.7%). Subgroup analysis of EQ‑5D outcomes across studies revealed minimal but statistically significant difference between strategies (pooled mean difference 0.084; 95% CI: 0.033 to 0.134). Mortality (hazard ratio 0.913; 95% CI 0.167–4.98) and transfusion reactions (risk difference − 0.01; 95% CI-0.10 to 0.09) did not differ. Notably, liberal thresholds required average of 4 additional RBC units per patient (95% CI 1.43–6.79), raising concerns about iron overload (rise in ferritin; mean difference 868 µg/L; 95% CI 482–1255). Conclusion: Limited evidence suggests that liberal transfusion strategies in MDS may improve short-term QoL but at the cost of increased transfusion burden, with no clear impact on survival or safety. A patient-centred, multidisciplinary approach remains essential when tailoring transfusion thresholds.
- 21 November 2024
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 32 (1) , 112-117
Potential advantage of therapeutic plasma exchange over intravenous immunoglobulin in children with axonal variant of Guillain-Barré syndrome: A report of six paediatric cases
- 21 November 2024
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 32 (1) , 112-117
Potential advantage of therapeutic plasma exchange over intravenous immunoglobulin in children with axonal variant of Guillain-Barré syndrome: A report of six paediatric cases